Latest news
Latest news
Changing issuance patterns, tight mezzanine spreads and investor demand deliver bumper crop of deals
Deal follows Macquarie's acquisition of Spire, which issued previous Aurium CLOs
Pim van Schie, a portfolio manager at Neuberger, discusses rising investor appetite for CLO mezzanine tranches
More articles
More articles
-
Valeant Pharmaceuticals, the biggest obligor in US CLOs, is understood to be selling off assets in an attempt to pay down debt. But it may not be the shot in the arm the sector is after, writes Sam Kerr. -
With aggressive leveraged loan repricing hitting the returns to CLO structures, managers are taking a variety of steps to protect their portfolios.
-
Derivatives and fixed income valuation and risk analytics provider FINCAD has added securitization to its coverage.
-
With Europe’s leveraged loan market undergoing a “repricing frenzy”, CLO managers are looking to refinance deals coming out of non-call periods over the next few months in order to protect equity returns in those deals.
-
The US new issue CLO market finished last week with a flurry of deals.
-
The US new issue CLO market sprang to life this week, cheered by investors who have complained about the high volume of refinancing and reset activity that has dominated the market in October.
-
US CLO investors, managers and analysts say that a dip in credit quality is the biggest issue facing the market next year, against the backdrop of soaring leveraged loan prices and rising rates hindering the ability of companies to pay off debt.
-
3i has sold its debt management business to Bahrain-based private equity firm Investcorp, while Tikehau Capital will boost its CLO business with the acquisition of Lyxor’s €700m European debt funds.
-
Spreads on US CLOs are grinding ever tighter, though not from improving sector specific fundamentals. Observers say that tighter pricing is being determined by broad issues driving investors to the sector.
